Blood loss remains a major concern during surgery and can increase the morbidity of the intervention. The use of topical haemostatic agents to overcome this issue therefore becomes necessary. Fibrin sealants are promising haemostatic agents due to their capacity to promote coagulation, but their effectiveness and applicability need to be improved. We have compared the haemostatic efficacy of a novel nanostructured fibrin-agarose hydrogel patch, with (c-NFAH) or without cells (a-NFAH), against two commercially available haemostatic agents in a rat model of hepatic resection.
| INTRODUCTION
Uncontrolled haemorrhage remains an important intraoperative complication that may change patient follow-up after major surgical interventions and is responsible for high rates of mortality and morbidity and longer hospitalization duration (Brustia, Granger, & Scatton, 2016) . In particular, hepatic resection often requires perioperative transfusion due to intraoperative blood loss. Despite improvements in existing surgical, anaesthesia preassessment and/or other perioperative interventions (suturing, cauterization, patient positioning, and use of special equipment such as water jet, radiofrequency ablation, or cavitron ultrasonic surgical aspirator), the reduction of bleeding during hepatic surgery remains transitory or incomplete (Berrevoet & Hemptinne, 2007; Brustia et al., 2016; Chouillard, Gumbs, & Cherqui, 2010; Eeson & Karanicolas, 2016; Smyrniotis, Farantos, Kostopanagiotou, & Arkadopoulos, 2005; Tympa et al., 2012; Zhu et al., 2015) . Accordingly, topical haemostatic agents are usually required to prevent intraoperative or post-operative blood loss (Eeson & Karanicolas, 2016; Moggia et al., 2016) .
Several haemostatic agents approved by Food and Drug Administration have been developed to maintain haemostasis in multiple surgical procedures. Topical haemostatic agents can be classified according to their composition in matrix-based, fibrin and/or thrombin-based and combined products (matrix + fibrin and/or thrombin-based haemostatic agent). Matrix-based products form a barrier that interrupt blood flow facilitating clot formation (e.g., Gelfoam, Hemopatch) whereas fibrin and/or thrombin-based products provide factors and compounds that promote generation of fibrin clots (e.g., Tissucol, Evicel). Combined products (e.g., Tachosil, Evarrest) seem to achieve better results (Brustia et al., 2016) .
Fibrin sealant derived from human plasma has become a popular haemostatic agent due to its capacity to imitate and promote the final step of the coagulation cascade (Mankad & Codispoti, 2001; MOSESSON, SIEBENLIST, & MEH, 2006) . Furthermore, fibrin sealant is the only Food and Drug Administration clinical material approved as a haemostatic sealant and adhesive agent for therapeutic use.
Despite recent advances in the field, however, overall haemostatic suitability in terms of effectiveness (time to haemostasis), applicability, or absence of rebleeding or undesired adhesion remains far from perfect and could be further improved (Spotnitz, 2014) .
We have previously developed a nanostructured fibrin and type VII agarose hydrogel (NFAH) as a scaffolding biomaterial compatible with multiple tissue models (Alaminos et al., 2006; Carriel et al., 2012 Carriel et al., , 2013 Carriel, Garzón, Campos, Cornelissen, & Alaminos, 2014; Garzón et al., 2014; Sanchez-Quevedo et al., 2007) . This biomaterial can be seeded with different cell types and has been characterized as a substitute for cornea, oral mucosa, and nerve (Carriel et al., 2017; Ionescu et al., 2011; Rodríguez et al., 2012) . This stromal-like substitute is composed mainly of human plasma and shows high flexible and elastic properties as well as mechanical strength (Mosesson et al., 2006; Scionti et al., 2014) . Moreover, fibroblasts and other cell types can be seeded inside the scaffold with good viability and function (Carriel et al., 2013 
| Karyotyping
For cytogenetic analysis, the karyotype with Bands-G of the fibroblast cell cultures was performed by the Andalusian Public Health System Biobank. To carry out analysis, first, the cells are incubated in medium supplemented with 0.1 mg/ml of colcemide for 4 hr. Later, they are washed with PBS, trypsinized, and centrifuged. The pellet are resuspended in a hypotonic solution of KCl (0.075 mol/L), washed to remove the cytoplasm, and the nuclei are fixed with methanol/acetic in a 3:1 ratio (vol/vol). Finally, the metaphases are resuspended in 1 ml of fixative and are fixed in slides. G bands with trypsin-Giemsa (GTG) are made, and a minimum of 20 metaphases are analysed for each cell line, assigning a karyotype formula according to the International System of Human Cytogenetic Nomenclature (McGowan-Jordan, Simons, & Schmid, 2016) . The karyotypes are analysed using a microscope Leica DM5500 and the Ikaros Karyotyping System (Metasystems).
| Generation of the NFAH pad
The protocol for NFAH production is an adaptation of methods described previously (Alaminos et al., 2006; Carriel et al., 2012; 2013; 2014; Garzón et al., 2014; Scionti et al., 2014) . To obtain the volume of fibrin-agarose hydrogel (FAH) needed to coat a six-well plate with 24 mm transwell inserts (3450; Corning Incorporated, Kennebunk, ME, USA), a 30-ml mixture was prepared as follows: 25 ml of human plasma (Tebu-bio, Le-Perray-en-Yvelines, France), 0.5 ml of tranexamic acid (Amchafibrin 500 mg, Rottapharm, Milan, Italy), and 2 ml of culture medium, with or without fibroblasts, was placed into a 50 ml conical tube. Subsequently, a solution containing 1.8 ml of 10% calcium chloride (B.Braun, Melsungen, Germany), 1.2-ml PBS, and 1.5 ml of liquid 2.2% type VII agarose (Sigma-Aldrich) was added. After mixing, 5 ml of the resulting solution was poured into each transwell, and the plate was left at 37°C for 2 hr. Once gelation was complete, the FAH was covered with culture medium and maintained at 37°C for 24 hr (plates remained in the incubator for a further 7 days when FAH contained cells), prior to nanostructuration (Figure 1a ).
Nanostructuration is a compression and dehydration process. This technique preserves the fibrin structure while removing most of its water content. As a consequence, rheological properties of FAH are changed increasing elasticity and resistance (Ionescu et al., 2011) . To All haemostatic agents were applied as round-shaped pads of 12-mm diameter for the short incision and 24 mm for the long incision. Time to haemostasis was defined as the time needed for the arrest of free blood leakage after application of the haemostatic agent. The timer was started at the moment of application of the haemostatic agent over the hepatic surface and was stopped when a complete cessation of blood extravasation through the hepatic resection surface was achieved.
Immediately postrecovery, rats were housed in individually ventilated cages with free access to food and water. If animals required analgesia, ketoprofen was administrated every 12 hr.
Rats were euthanized by cardiac puncture 24 hr after surgery to evaluate post-operative haemorrhage, presence of haematoma, migration of the haemostatic agent, and intra-abdominal adhesion of the haemostatic agent to adjacent intact tissues. Blood was also drawn for the measurement of cytokines by Enzyme-Linked ImmunoSorbent Assay (ELISA). The grade of adhesion was determined by a score of 0-2: 0, no adhesion; 1, thin adhesions separable by gravity; 2, thick adhesions not separable by gravity.
Sections of hepatic tissue attached to the haemostatic agent were fixed in 4% paraformaldehyde for histopathological analysis. 
| Microscopy analysis
Paraformaldehyde-fixed paraffin-embedded blocks of liver tissue were cut at a thickness of 4 μm, and sections were stained with the Trichrome Stain (Masson) Kit (Catalog N°HT15-1KT, Sigma-Aldrich) and haematoxylin-eosin (Catalog N°GHS316 and HT110116, Sigma-Aldrich), by standard methods. Sectioned liver samples were analysed by investigators blinded to the treatment groups.
Histological variables were studied by microscopic analysis and categorized as shown in Table 1 .
| Statistical analysis
Based on our preliminary data, the sample size was calculated to detect a significant effect d = 0.55, with a power of 80% at a level of significance of 5%. This requires a minimum of 10 animals per group (https://www.anzmtg.org/stats/PowerCalculator/PowerANOVA).
Data are presented as mean ± SEM. Significance was determined using the Mann-Whitney U test or the Kruskal-Wallis analysis of variance test with Dunn's post hoc multiple comparison test. Differences were considered significant at p ≤ 0.05. All statistical analyses were performed using GraphPad Prism 7.0 (GraphPad Software Inc., San Diego, CA). We next tested the haemostatic effect of the c-NFAH pad in a severe model of hepatic resection (long, 1.5-cm incision). We also included three additional treatment groups in this analysis: a-NFAH, to evaluate whether fibroblasts had a beneficial effect on the haemostatic process; FTC, to compare the effect of c-NFAH with another fibrin-based commercial haemostatic product; and PCC, to compare the fibrin-based products with a collagen-based matrix.
Results showed that a-NFAH presented the lowest time to haemostasis at 2.4 ± 0.58 s (N = 10, range = 1-5), followed by c-NFAH at 2.9 ± 1.72 s (N = 10, range = 1-7). Both treatments showed a significantly greater haemostatic effect than PCC We next measured the levels of inflammatory factors in blood (at sacrifice) by ELISA, to test the inflammatory response at 24 hr following surgery (minimum of N = 7 animals per group). Regarding CRP levels, there were no significant differences between the a-NFAH, PCC, or FTC groups. However, CRP levels in the c-NFAH group were significantly higher than in the a-NFAH (p < 0.01), PCC (p < 0.05), or FTC (p < 0.001) groups (Figure 3a) . By contrast, the PCC group had significantly higher IL-1β levels than the a-NAFH or FTC groups (p < 0.05 and p < 0.001, respectively), whereas no differences were observed between c-NAFH, a-NAFH, and FTC groups (Figure 3b ). Furthermore, there were no significant differences in TNF-α levels between the a-NAFH group and the other three groups. However, the c-NAFH and FTC groups presented significantly higher levels than the PCC group (p < 0.01 and p < 0.05, respectively; Figure 3c ).
Histopathological variables, including haemorrhage, inflammation, and necrosis, were scored by blinded investigators according to the criteria described in Section 2. Representative images of the different grades of these variables are shown in Figure 4a . Both NFAH treatments showed lower haemorrhage, inflammatory response, and necrosis than PCC or FTC treatment. Further, the PCC group displayed more overall haemorrhage than the other groups. Conversely, the c- In a preliminary mild model study, c-NFAH showed greater haemostatic ability than the commercially available PCC matrix, prompting us to extend the study to a more severe model of hepatic incision. We also included the a-NFAH and FTC substrates in the study. a-NFAH was incorporated to assess whether the presence of fibroblasts provided a significant improvement in haemostasis (Costa-Almeida, Soares, & Granja, 2017) against the hypothesis that NFAH matrix could account for most of the haemostatic potential of the pads. FTC was incorporated to compare NFAH with a commercial haemostatic agent of similar composition. In this second analysis, c-NFAH and a-NFAH showed significantly lower time to haemostasis when compared with PCC and FTC; however, no significant differences were found between c-NFAH and a-NFAH.
Interestingly, in our hepatic surgical model, better haemostasis was reached using PCC than FTC, in line with a previous report (Lewis et al., 2014) .
In addition to time to haemostasis, we investigated other relevant outcomes such as incidence of haematoma formation, rebleeding and/or adhesions, levels of some inflammatory factors, and histology.
In contrast to the PCC and FTC treatments, both NFAH treatments showed a complete absence of haematoma formation and a low incidence of thick adhesions. These results might be due to a combination of the fast adherence of the NFAH pads, their lower time to haemostasis and their easier applicability to the wound surface. Contrary to a previous study, PCC had a higher incidence of haematoma formation than FTC in our model (Lewis et al., 2014) . Overall, a-NFAH was superior to the other groups regarding inflammatory factors, with levels equal to or lower than those found with the commercial products. However, c-NFAH had significant higher CRP levels than a-NFAH, likely due to the presence of cells. Similarly, NFAH treatment groups had lower grades of haemorrhage, inflammation, and necrosis.
An additional advantage of NFAHs is the smaller adherent effect on surrounding tissue in contrast with hemostats PCC and FTC. This feature can be a great asset to certain types of surgeries.
Our novel NFAH matrix is composed of a nanostructured fibrin-type VII agarose hydrogel that is completely absorbable and biodegradable and displays optimal biomechanical and rheological properties (flexibility, elasticity, and mechanical strength), with no tissue reactivity or antigenicity (Garzón et al., 2009; Fernández-Valadés Gámez et al., 2017) . Agarose is a polysaccharide extracted from certain algae that, besides being an inert product from an immunological perspective, offers natural adhesiveness. This feature, as well as the high fibrin content (such that it does not rely on fibrinogen conversion as FTC, for example), may contribute to the haemostatic effectiveness of NFAH and the rapid sealing of damaged tissue.
We need to mention that, besides the fibrin, other agents used in the formulation may contribute to the haemostatic effect of our NFAH. Tranexamic acid is a procoagulant drug that has an antifibrinolytic action and has been successfully used to reduce blood loss in several types of surgery (Meng, Pan, Xiong, & Liu, 2018; Queiroz et al., 2018; Suh, Kyung, Han, Cheong, & Lee, 2018; Zilinsky et al., 2019) . Indeed, it has been shown that the use of tranexamic acid and fibrinogen reduces blood loss and improves coagulation measurements in a porcine model of liver injury (Zentai et al., 2016) . However, the final content of tranexamic acid in the NFAH (1.6% or 8.3 mg) is quite low compared with the concentrations used for topical application (100-500 mg) or intravenously (1 g). Similarly, calcium chloride accelerates fibrin polymerization and clot formation (Brass, Forman, Edwards, & Lindan, 1978) , and although it is used to stabilize the matrix, we cannot exclude that the haemostatic effect of the NFAH is enhanced by the presence of calcium.
Furthermore, NFAH has been used as a scaffolding matrix for different artificial tissues, with excellent clinical results in terms of safety thus far (ClinicalTrials.gov: NCT01765244).
The surgical model developed herein may not be absolutely predictive for clinical use. Nevertheless, it does allow a standardized evaluation of our novel hydrogel pad against two commercially available haemostatic agents. As this study was designed as a proofof-concept, we chose rats as our first experimental model, mainly due to their easy availability and handling and low cost. Further investigations are warranted to evaluate NFAH haemostatic effectiveness in other surgical-based experimental models. Indeed, studies to evaluate long-term safety and a method of NFAH preservation are currently underway in our laboratory.
As mentioned, no optimal haemostatic agent exists to date, and uncontrolled surgical bleeding remains an unmet clinical need. Any improvement in terms of reduction of time to haemostasis and/or FIGURE 3 Inflammation factor levels in rats subjected to long hepatic incision after haemostatic treatment. (a) CRP, (b) IL-1β, and (c) TNF-α blood levels measured by ELISA after 24 hr in rats with long hepatic incision treated with c-NFAH, a-NFAH, PCC, or FTC. Data represent mean ± SEM. Data were analysed using Kruskal-Wallis analysis of variance test followed by Dunn's post hoc test (N = 7-15); *p < 0.05; **p < 0.01; ***p < 0.001. c-NFAH: cellularizednanostructurated fibrin-agarose hydrogel; a-NFAH: acellularnanostructurated fibrin-agarose hydrogel; FTC: fibrinogen/thrombincoated collagen pad (Tachosil®); PCC: protein-reactive polyethylene glycol-coated collagen pad (Hemopatch®); CRP: C-reactive protein; IL-1β: interleukin 1 beta; TNF-α: tumour necrosis factor alpha rebleeding, along with ease of use and applicability, could pose a huge impact not only in hospital costs but also in patients' quality of life. We show here that NFAH has excellent haemostatic and sealing properties, and we believe that these results will pave the way for this new product to be part of the arsenal of haemostatic agents in multiple surgical procedures in the future.
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